scispace - formally typeset
Search or ask a question

Showing papers in "Oncology Times UK in 2005"




Journal ArticleDOI
TL;DR: In this article, the authors reported a case of Sweet syndrome secondary to the administration of imatinib to treat CML, which is the first time that Sweet syndrome has been reported with its use.
Abstract: Background Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use. Observations We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib. Conclusion Greater awareness of the adverse effects of imatinib and the characterization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.

14 citations


Journal ArticleDOI

7 citations




Journal ArticleDOI

3 citations







Journal ArticleDOI
TL;DR: The National Youth Tobacco Survey (NYTS), conducted by CDC in 2004, provided estimates of current use of tobacco products and selected indicators related to tobacco use, including youth exposure to tobacco-related media and access to cigarettes.
Abstract: T wo of the national health objectives for 2010 are to reduce the prevalence of any tobacco use during the preceding month to 21% or less and the prevalence of current cigarette use to 16% or less among high school students (objectives 27-2a and 27-2b). The National Youth Tobacco Survey (NYTS), conducted by CDC in 2004, provided estimates of current use of tobacco products and selected indicators related to tobacco use, including youth exposure to tobacco-related media and access to cigarettes. This report summarizes data from the 2004 NYTS and describes changes in tobacco use and indicators related to tobacco use since 2002. Between 2002 and 2004, middle school students reported decreases in pipe use, seeing actors using tobacco on television or in movies, and seeing advertisements for tobacco products on the Internet.







Journal ArticleDOI
TL;DR: The Kras-driven mouse lung tumors were significantly similar to adenocarcinoma-type lung cancers but not to squamous cell cancers, which confirms the accuracy of the histology results the team reported earlier.
Abstract: If advanced cancer is so difficult to treat, then Dr. Jacks reasoned that researchers need to focus on earlier stages to increase the odds of tumor detection and treatment. But when one asks where cancers come from in this model or in lung cancer or in solid tumors in general, he said, “The answer is, ‘We don’t know.’” Mature lung tissue contains more than 40 cell types. Two of these cell types, alveolar type 2 cells and Clara cells, share biomarkers with NSCLC cells, indicating that tumors might arise from these cells types. Recently, however, Dr. Jacks’ group identified a progenitor cell that gives rise to both alveolar type 2 cells and clara cells, which they named bronchioalveolar stem cells (BASCs). Within one week of Kras activation by Creadenovirus, BASC proliferation increased. BASCs are present in healthy animals in the bronchioalveolar ductal junction, a region previously known to be involved in repair. The scientists uncovered evidence that BASCs proliferate when other cell types are damaged or removed. Also found was that BASCs differentiate into Clara cells and alveolar types 1 and 2 cells, and have the ability for self-renewal. Although the researchers saw evidence of these cells proliferating shortly after the Kras mutation was activated by Cre recombinase, few BASCs are found in established tumors. The few that were present existed in clusters. Dr. Jacks speculated that BASCs are cancer stem cells and responsible for driving tumor growth. For therapies to have lasting effects, he said, it will be necessary to kill off such cells. But at least now researchers have an idea what cells they need to target. “This is an example of going from tumor biology to normal biology,” Dr. Jacks said. But how similar are these mouse cancers relative to human disease? To find out, the team performed microarrays on tumor samples from the animals and—in collaboration with Todd Golub, MD, a Howard Hughes Investigator at Harvard Medical School and Dana-Farber Cancer Institute—compared the results to microarrays from human NSCLC tumors. The Kras-driven mouse lung tumors were significantly similar to adenocarcinoma-type lung cancers but not to squamous cell cancers, which confirms the accuracy of the histology results the team reported earlier. Furthermore, the microarrays from the animal models were very clean, with samples from one animal looking much like those of another, which might be expected given their uniform genetic backgrounds and environments. Taking advantage of this homogeneity, the team found a Kras gene signature typical of both the animal and human tumors. “This is an example of where mouse models didn’t just follow but led in identifying genes important in human cancers,” Dr. Jacks said. Dr. Kastan noted that the model Dr. Jacks described is not yet a typical model—“It is the cutting edge, but I think it will be the paradigm for animal models in the future.” T PAGE 26 / SEPTEMBER 10, 2005










Journal ArticleDOI
TL;DR: A new brochure aimed at helping patients through an often-difficult process of optimizing health care as well as psychosocial care and the first distribution of a 54-page brochure was discussed at the 4th World Conference on Breast Cancer.
Abstract: H ALIFAX, Nova Scotia—When faced with a diagnosis of advanced breast cancer, women are faced with a landscape of questions, choices, and conflicting emotions that often require more than a compass for successful navigation. As discussed here at the 4th World Conference on Breast Cancer, a recent study conducted in British Columbia found that just in the medical arena the average woman with advanced breast cancer will consult with an average of 32 different clinicians in the course of her treatment. Joanne Stephen, PhD, a research consultant at the Sociobehavioural Research Centre within the BC Cancer Agency in Vancouver, reported that the range in the number of clinicians was 13 to 97. “The BC Cancer Agency has identified the integration of cancer-control programs in the community as a primary organizational objective,” Dr. Stephen said in a poster presentation. Her presentation coincided with the first distribution of a 54-page brochure, Navigating Your Path: A Guide for People with Advanced Breast Cancer, discussed at a plenary session of the conference by Deborah Rusch, Director of the Alliance for Breast Cancer Information and Support, located in British Columbia and the Yukon. The information is aimed at helping patients through an often-difficult process of optimizing health care as well as psychosocial care.